NBC Nightly News Spotlights GLP-1 Medication Lawsuits Over Vision Loss
Event summary
- NBC Nightly News aired a segment on September 22, 2026, featuring Parker Waichman client Diane Wirth, who suffered permanent vision loss after using Wegovy.
- The report highlighted the alleged link between GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION).
- Parker Waichman's Jason S. Goldstein, Co-Chair of the Plaintiffs' Executive Committee in the federal GLP-1 NAION litigation (MDL No. 3163), was also featured.
- The litigation involves claims against manufacturers of Ozempic, Wegovy, Mounjaro, and Zepbound for failing to warn about NAION risks.
- Over 300 lawsuits have been filed against GLP-1 medication manufacturers over vision loss allegations.
The big picture
The NBC Nightly News segment amplifies the legal and regulatory challenges facing GLP-1 medication manufacturers, highlighting the human impact of alleged adverse effects. This comes as the pharmaceutical industry faces increasing scrutiny over the safety profiles of widely prescribed drugs. The litigation could set a precedent for how drug manufacturers handle and disclose potential risks associated with their products.
What we're watching
- Regulatory Scrutiny
- How regulatory bodies will respond to the growing evidence linking GLP-1 medications to NAION and potential changes in warning labels.
- Litigation Impact
- The pace at which the multidistrict litigation (MDL No. 3163) progresses and the potential financial implications for GLP-1 medication manufacturers.
- Market Reaction
- Whether the negative publicity and legal challenges will affect the market share and prescribing rates of GLP-1 medications.
Related topics